Table 2.
Conference abstracts included in the study.
| Author, Type of Study | Patient Population | Radiation Dosage, Gy | Activity, GBq | Microsphere Type: Number of Patients Treated | RECIST, WHO | Survival Outcomes | Follow-Up Information | Notes and Other Findings |
|---|---|---|---|---|---|---|---|---|
| Helmberger, T. et al. (2021) PS [62] |
120 pts NM |
- | Median (entire liver): 1.3 Right lobe of liver: 1.2 Left lobe of liver: 0.8 |
Resin: 120 | - | Median OS: 14.7 mo Median PFS: 5.7 mo |
24 mo | - |
| Lorenzoni, A. et al. (2020) RS [63] |
23 pts 30 SIRTs (7 pts with multiple SIRT treatments) Mixed * |
Mean TD: 309 NTD: 42.4 |
2.5 | Glass: 30 | mRECIST at unspecified time: CR: 3% PR: 3% SD: 87% PD: 7% |
Median OS: 21 mo Median PFS: 9 mo |
- | Mean TD stable disease lesions: 280 Gy, responding lesions (CR + PR): 384 Gy |
| Core, J. et al. (2020) RS [64] |
32 pts 42 SIRT (Number of pts with multiple SIRT treatments unspecified) NM |
Median TD: 253 | - | - | mRECIST at 3 mo (36 pts): CR: 33.3% PR: 58.3% SD: 8.3% PD: 0 |
Median OS not reached. | Median FU: 10.9 mo | - |
| Pettinato, C. et al. (2019) RS [65] |
35 pts mixed |
Mean TD: 455.7 Mean NTD: 13.9 |
Mean: 1.4 | Resin: 35 | RECIST 1.1 at unspecified time: OR: 20% mRECIST at unspecified time: OR: 70% EASL at unspecified time: OR: 60% |
Mean OS: 15.3 mo | 4 deaths | - |
| Schatka, I. et al. (2017) RS [66] | 33 pts refractory |
- | Median: 1.8 | Resin: 33 | - | Median OS: 8 mo | - | - |
| Boni, G. et al. (2017) PS [67] |
20 pts, 29 SIRT (3 pts with multiple SIRT treatments) mixed |
- | Mean: 0.97 | Resin: 29 | - | Median TTP: 7.3 mo |
- | - |
| Peterson, J. et al. (2010) RS [68] |
9 pts NM |
- | Median: 41 mCi † | Resin: 9 | (Criteria not mentioned) (7 pts) PR: 57%PD: 43% |
OS at 9 mo: 89% | - | - |
CR, complete response; NTD, nontumor (liver) dose; NM, (patient population in terms of previous treatments received) not mentioned; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; PS, prospective study; RS, retrospective study; SD, stable disease; SIRT, selective internal radiation therapy; TD, tumor dose; TTP, time to progression. * Mixed: treatment naïve and refractory cases. † mCi: delivered activity measure.